Clinical use of anti-vascular endothelial growth factor monoclonal antibodies in metastatic colorectal cancer

Pharmacotherapy

Volumn 28, Issue 11 PART 2, 2008, Pages

  Chase, Judy L ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Bevacizumab; Chemotherapy; CRC; Metastatic colorectal cancer; Vascular endothelial growth factor; VEGF

Indexed keywords

ANTINEOPLASTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEVACIZUMAB; BIOCHEMICAL MARKER; CALCIUM CHANNEL BLOCKING AGENT; CAPECITABINE; CELECOXIB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FLUOROURACIL; FLUOROURACIL PLUS LEUCOVORIN; IRINOTECAN; NONSTEROID ANTIINFLAMMATORY AGENT; OXALIPLATIN; PLACEBO; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; WARFARIN;

ABDOMINAL PAIN; ADJUVANT THERAPY; ANOREXIA; BILE DUCT FISTULA; BLADDER FISTULA; BLEEDING; BRONCHOPLEURAL FISTULA; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; CONSTIPATION; COST OF ILLNESS; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DISEASE FREE SURVIVAL; DIVERTICULITIS; DOSE RESPONSE; DRUG ACTIVITY; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; ECONOMIC ASPECT; EPISTAXIS; FISTULA; HEADACHE; HEALTH INSURANCE; HUMAN; HYPERTENSION; INFUSION RATE; MEDICARE; METASTASIS; MONOTHERAPY; MORTALITY; NAUSEA; NEPHROTIC SYNDROME; PROTEINURIA; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REIMBURSEMENT; REVIEW; SKIN IRRITATION; STOMATITIS; SURVIVAL TIME; THROMBOEMBOLISM; TRACHEOESOHAGEAL FISTULA; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VAGINA DISEASE; VOMITING; WEAKNESS; WOUND HEALING IMPAIRMENT;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASM METASTASIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 55549102649     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.28.11-supp.23S     Document Type: Review

References (49)

1. Ellis LM, Takahashi Y, Liu W, Shaheen RM. Vascular endothelial growth factor in human colon cancer: biology and therapeutic implications. Oncologist 2000;5(suppl 1):11-15.
2. Soria JC, Fayette J, Armand JP. Molecular targeting: targeting angiogenesis in solid tumors. Ann Oncol 2004;15(suppl 4):iv223-7.
3. Los M, Roodhart JM, Voest EE. Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer. Oncologist 2007;12:443-50.
4. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-76.
5. Morabito A, De Maio E, Di Maio M, Normanno N, Perrone F. Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions. Oncologist 2006;11:753-64.
6. George ML, Tutton MG, Janssen F, et al. VEGF-A, VEGF-C, and VEGF-D in colorectal cancer progression. Neoplasia 2001;3:420-7.
7. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FLO/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003;21:60-5.
8. Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006;3:24-40.
9. Calvani M, Trisciuoglio D, Bergamaschi C, Shoemaker RH, Melillo G. Differential involvement of vascular endothelial growth factor in the survival of hypoxic colon cancer cells. Cancer Res 2008;68:285-91.
10. Genentech, Inc. Avastin (bevacizumab) package insert. South San Francisco, CA; 2008.
11. Gerber HP, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 2005;65:671-80.
12. Giantonio BJ, Catalano PJ, Meropol NJ, et al, for the Eastern Cooperative Oncology Group. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group study E3200. J Clin Oncol 2007;25:1539-44.
13. Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004;10:145-7.
14. Giantonio BJ, Levy DE, O'Dwyer PJ, Meropol NJ, Catalano PJ, Benson AB III, for the Eastern Cooperative Oncology Group. A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200. Ann Oncol 2006;17:1399-403.
15. Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005;23:3706-12.
16. Kozloff M, Hainsworth J, Badarinath S, et al. Efficacy of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: updated results from a large observational registry in the U.S. (BRiTE) [abstract 3537]. Presented at the annual meeting of the American Society of Clinical Oncology, Atlanta, GA, June 2-6, 2006.
17. Fuchs CS, Marshall J, Mitchell E, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 2007;25:4779-86.
18. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
19. Sobrero AF, Young S, Balcewicz M, et al. Phase IV study of first-line bevacizumab plus irinotecan and infusional 5-FU/LV in patients with metastatic colorectal cancer: AVIRI [abstract 4068]. J Clin Oncol 2007;25:S180.
20. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
21. O'Dwyer PJ. The present and future of angiogenesis-directed treatments of colorectal cancer. Oncologist 2006;11:992-8.
22. U.S. National Institutes of Health. ClinicalTrials.gov. Clinical trial search result. Phase II study of Avastin + Erbitux + Irinotecan as 2nd line treatment of colorectal cancer. Available from www.clinicaltrials.gov/ct2/ show/NCT00681876?term=cetuximab+irinotecan+bevacizumab&rank=1. Accessed July 20, 2008.
23. Grothey A, Sugrue M, Hedrick E, et al, for the BRiTE Study Investigators. Association between exposure to bevacizumab (BV) beyond first progression (BBP) and overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): results from a large observational study (BRiTE) [abstract 4036]. J Clin Oncol 2007;25:S172.
24. Benson AB III. New approaches to assessing and treating early-stage colon and rectal cancers: cooperative group strategies for assessing optimal approaches in early-stage disease. Clin Cancer Res 2007;13(suppl 22):S6913-20.
25. F. Hoffmann-La Roche Ltd. Clinical trial registry search result Available from www.roche-trials.com/patient/trials/trial12.html. Accessed July 4, 2008.
26. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: colon cancer, V.2.2008. Available from www.nccn.org/professionals/physician_gls/PDF/colon.pdf. Accessed January 10, 2008.
27. Tuma RS. Success of bevacizumab trials raises questions for future studies. J Natl Cancer Inst 2005;97:950-1.
28. Drevs J, Zirrgiebel U, Schmidt-Gersbach CI, et al. Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials. Ann Oncol 2005;16:558-65.
29. Selvakumaran M, Yao KS, Feldman MD, O'Dwyer PJ. Antitumor effect of the angiogenesis inhibitor bevacizumab is dependent on susceptibility of tumors to hypoxia-induced apoptosis. Biochem Pharmacol 2008;75:627-38.
30. Hochster HS, Hart LL, Ramanathan RK, Hainsworth JD, Hedrick EE, Childs BH. Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): final analysis of the TREE study [abstract 3510]. J Clin Oncol 2006;24:S148.
31. Berry SR, Cunningham D, Michael M, et al, for the First BEAT Investigators. Preliminary safety of bevacizumab with first-line FOLFOX, CAPOX, FOLFIRI and capecitabine for mCRC_first B.E.A.Trial [abstract 3534]. Presented at the annual meeting of the American Society of Clinical Oncology, Atlanta, GA, June 2-6, 2006.
32. Hedrick E, Kozloff M, Hainsworth J, et al. Safety of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: updated results from a large observational registry in the U.S. (BRiTE) [abstract 3536]. J Clin Oncol 2006;24:S155.
33. Kilickap S, Abali H, Celik I. Bevacizumab, bleeding, thrombosis, and warfarin [letter]. J Clin Oncol 2003;21:3542.
34. Scappaticci FA, Skillings JR, Holden SN, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007;99:1232-9.
35. van Heeckheren WJ, Ortiz J, Cooney MM, Remick SC. Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker? J Clin Oncol 2007;25:2993-5.
36. Hambleton J, Novotny WF, Hurwitz H, et al. Bevacizumab does not increase bleeding in patients with metastatic colorectal cancer receiving concurrent anticoagulation [abstract 3528]. J Clin Oncol 2004;22:252.
37. Saif MW, Elfiky A, Salem RR. Gastrointestinal perforation due to bevacizumab in colorectal cancer. Ann Surg Oncol 2007;14:1860-9.
38. Kretzschmar A, Cunningham D, Berry S, for the First BEAT Investigators. Incidence of gastrointestinal perforations and bleeding in patients starting bevacizumab treatment in first-line mCRC without primary tumour resection: preliminary results from the first BEATrial [abstract 248]. Presented at the American Society of Clinical Oncology gastrointestinal cancers symposium, San Francisco, CA, January 26-28, 2006.
39. Scappaticci FA, Fehrenbacher L, Cartwright T, et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 2005;91:173-80.
40. Kabbinavar FF, Schulz J, McCleod M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005;23:3697-705.
41. McKoy JM, Patel J, Courtney DM, Bolden CR, Bennett CL. Bevacizumab-associated diverticulitis. Community Oncol 2008;5:31-2.
42. Almhanna K, Pelley RJ, Thomas Budd G, Davidson J, Moore HCF. Subcutaneous implantable venous access device erosion through the skin in patients treated with anti-vascular endothelial growth factor therapy: a case series. Anticancer Drugs 2008;19:217-19.
43. Reidy DL, Chung KY, Timoney JP, et al. Bevacizumab 5 mg/kg can be infused safely over 10 minutes. J Clin Oncol 2007;25:2691-5.
44. Benson AB III. Epidemiology, disease progression, and economic burden of colorectal cancer. J Manag Care Pharm 2007;13(suppl S-c):S5-18.
45. Tappenden P, Jones R, Paisley S, Carroll C. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer. Health Technol Assess 2007;11:1-128.
46. Jansman FG, Postma MJ, Brouwers JR. Cost considerations in the treatment of colorectal cancer. Pharmacoeconomics 2007;25:537-62.
47. Genentech,Inc. Access solutions. Reimbursement: coding information. Available from www.genentechaccesssolutions.com/avastin/ professional/coverage/reimbursement-coding.jsp. Accessed July 3, 2008.
48. Centers for Medicare and Medicaid Services. Press release; Medicare launches efforts to improve care for cancer patients. Released January 28, 2005. Available from www.cms.hhs.gov/apps/media/press/release.asp?Counter= 1337. Accessed July 2, 2008.
49. National Cancer Institute. Clinical trials. Clinical trials covered under the Medicare anti-cancer drugs. National coverage decision. Available from www.cancer.gov/clinicaltrials/developments/NCD179N. Accessed July 2, 2008.